var data={"title":"Centruroides antivenom: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Centruroides antivenom: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/8138?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=centruroides-antivenom-patient-drug-information\" class=\"drug drug_patient\">see &quot;Centruroides antivenom: Patient drug information&quot;</a> and <a href=\"topic.htm?path=centruroides-antivenom-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Centruroides antivenom: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13215077\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Anascorp</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13168364\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antivenin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13168394\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Scorpion envenomation:</b> IV: <b>Note:</b> Initiate therapy as soon as possible after scorpion sting. Initial: 3 vials (containing &le;360 mg total protein and &ge;450 LD50 [mouse] neutralizing units); may administer additional vials in 1-vial increments every 30 to 60 minutes as needed. Typical dosage range: 1 to 5 vials (Boyer 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13168393\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=centruroides-antivenom-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Centruroides antivenom: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Scorpion envenomation:</b> IV: Refer to adult dosing. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13168395\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13168396\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13168512\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Anascorp:  (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20452408\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13168397\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Administer over 10 minutes; monitor for return of symptoms of envenomation and repeat as needed. Medications (eg, epinephrine, corticosteroids, diphenhydramine) and equipment for resuscitation should be readily available in case of hypersensitivity reactions. Avoid IM since the time to peak blood concentration may be prolonged with this route of administration (Turri, 2011; Vasquez, 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13168365\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Scorpion envenomation: </b>Treatment of scorpion envenomation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13168372\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (2%), headache (2%), lethargy (1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (3%), pruritus (2%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Vomiting (5%), nausea (2%), diarrhea (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Myalgia (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Rhinorrhea (2%), cough (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Aspiration, ataxia, chest tightness, hypersensitivity, hypoxia, ocular edema, palpitations, pneumonia, respiratory distress, serum sickness (delayed) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13168369\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no contraindications listed within the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13168370\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concern related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute hypersensitivity reactions: Derived from equine (horse) immune globulin F(ab&rsquo;)<sub>2</sub> fragments; anaphylaxis and anaphylactoid reactions are possible, especially in patients with known allergies to horse protein. However, due to the lower protein content, purity, and absence of the immunogenic Fc portion of the immunoglobulin, serious adverse events are uncommon; in a prospective study (n=1,534), the incidence of acute antivenom reactions and type 3 immune reactions was 0.2% (n=3) and 0.5% (n=8), respectively (Boyer 2013). Patients who have had previous treatment with <i>Centruroides</i> immune F(ab&rsquo;)<sub>2</sub> or other equine-derived antivenom/antitoxin may be at a higher risk for hypersensitivity reactions. In patients who develop an anaphylactic reaction, discontinue the infusion and administer emergency care. Immediate treatment (eg, epinephrine 1 mg/mL, corticosteroids, diphenhydramine) should be available.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Delayed serum sickness: Delayed serum sickness may occur, usually within 2 weeks; monitor patients with follow-up visits for signs and symptoms (eg, arthralgia, fever, myalgia, rash).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form related issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cresol: Product may contain small amounts of cresol resulting from the manufacturing process; local reactions and myalgias may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Disease transmission: Product of equine (horse) plasma; may potentially contain infectious agents (eg, viruses) which could transmit disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299002\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13225889\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=16767&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13168366\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13168367\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003). Pregnant women experiencing symptoms refractory to reasonable doses of opioids or other systemic effects which pose a danger to the patient or fetus should be considered for antivenom therapy (Brown 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21099219\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if this product is excreted into breast milk. The manufacturer recommends caution be used if administered to a nursing woman.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13168399\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Signs and symptoms of envenomation (eg, opsoclonus, involuntary muscle movement, slurred speech, paresthesias, respiratory distress, salivation, frothy sputum, vomiting). Monitor for signs and symptoms of acute antivenom hypersensitivity reactions (eg, urticaria, dyspnea); follow-up visits for signs and symptoms of serum sickness (eg, arthralgia, fever, myalgia, rash).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13168385\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Contains venom-specific F(ab&rsquo;)<sub>2</sub> fragments of IgG which bind and neutralize venom toxins; thereby helping to remove the toxin from the target tissue and eliminate it from the body.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13168387\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset: Time to resolution of symptoms: Adults: 1.91 &plusmn; 1.4 hours; Children: 1.28 &plusmn; 0.8 hours; &gt;95% of all patients will experience resolution of symptoms within 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>dss</sub>: 13.6 L &plusmn; 5.4 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life, elimination: 159 &plusmn; 57 hours</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Bailey B. Are there teratogenic risks associated with antidotes used in the acute management of poisoned pregnant women? <i>Birth Defects Res A Clin Mol Teratol</i>. 2003;67(2):133-140.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/centruroides-antivenom-drug-information/abstract-text/12769509/pubmed\" target=\"_blank\" id=\"12769509\">12769509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boyer L, Degan J, Ruha AM, Mallie J, Mangin E, Alag&oacute;n A. Safety of intravenous equine F(ab')2: insights following clinical trials involving 1534 recipients of scorpion antivenom. <i>Toxicon</i>. 2013;76:386-393.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/centruroides-antivenom-drug-information/abstract-text/23916602/pubmed\" target=\"_blank\" id=\"23916602\">23916602</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boyer LV, Theodorou AA, Berg RA, et al. Antivenom for critically ill children with neurotoxicity from scorpion stings. <i>N Engl J Med</i>. 2009;360(20):2090-2098.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/centruroides-antivenom-drug-information/abstract-text/19439743/pubmed\" target=\"_blank\" id=\"19439743\">19439743</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brown SA, Seifert SA, Rayburn WF. Management of envenomations during pregnancy. <i>Clin Toxicol (Phila)</i>. 2013;51(1):3-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/centruroides-antivenom-drug-information/abstract-text/23298218/pubmed\" target=\"_blank\" id=\"23298218\">23298218</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Coorg V, Levitan RD, Gerkin RD, Muenzer J, Ruha AM. Clinical presentation and outcomes associated with different treatment modalities for pediatric bark scorpion envenomation. <i>J Med Toxicol</i>. 2017;13(1):66-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/centruroides-antivenom-drug-information/abstract-text/27487782/pubmed\" target=\"_blank\" id=\"27487782\">27487782</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tuuri RE, Reynolds S. Scorpion envenomation and antivenom therapy. <i>Pediatr Emerg Care</i>. 2011;27(7):667-675.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/centruroides-antivenom-drug-information/abstract-text/21730810/pubmed\" target=\"_blank\" id=\"21730810\">21730810</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vasquez H, Chavez-Haro A, Garcia-Ubbelohde W, et al. Pharmacokinetics of a F(ab&rsquo;)2 scorpion antivenom administered intramuscularly in healthy human volunteers. <i>Int Immunopharmacol</i>. 2010;10(11):1318-1324.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/centruroides-antivenom-drug-information/abstract-text/20849955/pubmed\" target=\"_blank\" id=\"20849955\">20849955</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 16767 Version 56.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F13215077\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F13168364\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F13168394\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F13168393\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F13168395\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F13168396\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F13168512\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F20452408\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F13168397\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F13168365\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F13168372\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F13168369\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F13168370\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299002\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F13225889\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F13168366\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13168367\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F21099219\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F13168399\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F13168385\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F13168387\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/16767|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=centruroides-antivenom-patient-drug-information\" class=\"drug drug_patient\">Centruroides antivenom: Patient drug information</a></li><li><a href=\"topic.htm?path=centruroides-antivenom-pediatric-drug-information\" class=\"drug drug_pediatric\">Centruroides antivenom: Pediatric drug information</a></li></ul></div></div>","javascript":null}